Yes

Ergot Derivative

Treatment of cerebrovascular insufficiency in primary progressive dementia, Alzheimer's dementia, and senile onset

C

Acute or chronic psychosis, hypersensitivity to ergot or any component

1% to 10%:

Miscellaneous: Sublingual irritation

Increased toxicity with dopamine

Ergoloid mesylates do not have the vasoconstrictor effects of the natural ergot alkaloids; exact mechanism in dementia is unknown; originally classed as peripheral and cerebral vasodilator, now considered a "metabolic enhancer"; there is no specific evidence which clearly establishes the mechanism by which ergoloid mesylate preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency

Absorption: Rapid yet incomplete

Serum half-life: 3.5 hours

Time to peak serum concentration: Within 1 hour

Adults: Oral: 1 mg 3 times/day up to 4.5-12 mg/day; up to 6 months of therapy may be necessary

Should not eat or drink while tablet dissolves under tongue

None reported

Contraindicated in individuals with psychosis

No information available to require special precautions

No effects or complications reported

Do not chew or crush sublingual tablets, allow to dissolve under tongue

Monitor blood pressure, heart rate

Capsule, liquid (Hydergine® LC): 1 mg

Liquid (Hydergine®): 1 mg/mL (100 mL)

Tablet: Oral: 0.5 mg

Gerimal®, Hydergine®: 1 mg

Sublingual: Gerimal®, Hydergine®: 0.5 mg, 1 mg